Drug Profile
K2P
Latest Information Update: 01 Aug 2002
Price :
$50
*
At a glance
- Originator Novartis; Pharmacia Corporation
- Class Anti-ischaemics; Thrombolytics
- Mechanism of Action Plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Myocardial infarction
Most Recent Events
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation